Trogarzo FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 12, 2022.
FDA Approved: Yes (First approved March 6, 2018)
Brand name: Trogarzo
Generic name: ibalizumab-uiyk
Dosage form: Injection
Company: TaiMed Biologics USA Corp.
Treatment for: HIV Infection
Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor for the treatment of multidrug resistant human immunodeficiency virus-1 (HIV-1) infection.
- Trogarzo is used in combination with other antiretroviral(s) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.
- Trogarzo is a recombinant humanized monoclonal antibody that works to block HIV-1 from infecting CD4+ T cells by binding to domain 2 of CD4 and interfering with post-attachment steps required for the entry of HIV-1 virus particles into host cells and preventing the viral transmission that occurs via cell-cell fusion.
- Trogarzo is administered as an intravenous infusion or intravenous push every 2 weeks.
- Warnings and precautions associated with Trogarzo include hypersensitivity reactions (infusion-related reactions and anaphylactic reactions), immune reconstitution inflammatory syndrome (IRIS), and embryo-fetal toxicity.
- Common adverse reactions include diarrhea, dizziness, nausea, and rash.
Development timeline for Trogarzo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
